Abstract:ID 92620 Poster Board 463 Background: Doxorubicin (DOX), an effective drug for many types of cancer, is associated with substantial cardiotoxicity. A 3-hour treatment of cardiomyoblast H9C2 cells with a low concentration of DOX (100 nM) can induce senescence-associated β-galactosidase (SA β-gal) staining, the gold standard of cell senescence. Here, we comprehensively characterized the phenotype of the DOX-induced senescent cardiomyocytes for the first time. We plan to use this cell model to search for effective treatments for DOX-induced cell senescence. Methods and Results: Using SA β-gal staining and cell growth rate as readouts, we assessed the concentration-dependent effect of DOX on H9C2 cell senescence. The cells were treated with DOX for 3 hours and subsequently cultured for 3 days. We found that a 50 nM concentration of DOX induced ~ 50% SA β-gal staining and completely inhibited cell growth. The DOX-induced H9C2 cell senescence was further confirmed by several well-accepted senescence markers including cell hypertrophy, increased p16 and p21 expression, increased Senescence Associated Secretory Phenotype (SASP) markers, arrested cell cycle at S phase and G2 phase, and increased ROS production. Interestingly, we found that 50 nM DOX increased mitochondrial respiration. Translationally, we found that mitochondrial-targeted tetrapeptide SS-31 (elamipretide, 1 μM), which is in clinical trials for heart failure and other diseases associated with mitochondrial dysfunction, partially attenuated 50 nM DOX-induced SA β-gal staining from 51.4% to 35.8%. SS-31 also prevented increases of the p16, p21, and SASP markers and mitigated mitochondrial ROS production. SS-31 also reversed the 50 nM DOX-induced elevation of mitochondrial respiration. However, 1 μM SS-31 failed to prevent the cell cycle arrest and cell growth retardation induced by 50 nM DOX. Conclusion: We determined that a 3-hour treatment with 50 nM DOX establishes a H9C2 cell senescence model. Treatment with mitochondrial-targeted SS-31 reverses the 50 nM DOX-induced cell senescence but not the cell cycle arrest. These data suggest that SS-31 is a promising drug to treat DOX-induced cardiomyocyte senescence. Keywords: Doxorubicin; H9C2 cell; Senescence; Mitochondria; SS-31 H.Z. received support from NIH (R35GM151226) and UAMS (Development Enhancement Awards for Proposals).

A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence

Deep Learning-Assisted High-Content Screening Identifies Isoliquiritigenin As an Inhibitor of DNA Double-Strand Breaks for Preventing Doxorubicin-Induced Cardiotoxicity

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Peficitinib ameliorates doxorubicin-induced cardiotoxicity by suppressing cellular senescence and enhances its antitumor activity

Protective effect of secretory APE1/Ref‐1 on doxorubicin‐induced cardiotoxicity via suppression of ROS and p53 pathway

SIRT1 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the Oxidative Stress and P38mapk Pathways

BN52021 Protects Rat Cardiomyocyte from Doxorubicin Induced Cardiotoxicity.

PARP-2 Mediates Cardiomyocyte Aging and Damage Induced by Doxorubicin Through SIRT1 Inhibition

Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation

Protosappanin A Protects DOX-Induced Myocardial Injury and Cardiac Dysfunction by Targeting ACSL4/FTH1 Axis-Dependent Ferroptosis

Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism

Prevention of Doxorubicin Cardiopathic Changes by a Benzyl Styryl Sulfone in Mice.

SS-31 Attenuates Doxorubicin-induced Cardiomyoblast H9C2 Cell Senescence

Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress

Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome

MicroRNA Therapy Confers Anti-Senescent Effects on Doxorubicin-Related Cardiotoxicity by Intracellular and Paracrine Signaling.

The TGF-β1/p53/PAI-1 Signaling Axis in Vascular Senescence: Role of Caveolin-1

PAI-1 Regulation of p53 Expression and Senescence in Type II Alveolar Epithelial Cells

Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity

Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling